AZN · AstraZeneca PLC
Price
Snapshot
50 fields · last close| Market Cap | $185.7B |
| P/E | 24.00 |
| Float | 1.50B |
| Beta | 1.39 |
| Volatility | 34.7% |
| Exchange | LSE |
| Sector | Pharmaceuticals |
| Cap tier | Large cap |
| Macro sensitivity | High |
| Clavix score | 76 |
| Price | 161.48 |
| Change | −2.00% |
| Prev Close | 164.77 |
| Open | 165.64 |
| Day Low | 162.24 |
| Day High | 165.74 |
| Avg Vol | 2 |
| Avg $ Vol | $282.4M |
| 52W High | 15,730.00 |
| 52W Low | 147.06 |
| 52W Pos | 0.1% |
| From High | −98.97% |
| From Low | +9.81% |
| Max DD 1Y | −25.71% |
| Spread | 0.10% |
| Liquidity | Normal |
| SMA 20 | −0.55% |
| SMA 50 | −4.77% |
| SMA 200 | −12.22% |
| RSI (14) | 50.1 |
| Vol 30D | 30.2% |
| Vol 90D | 31.1% |
| 1Y Range | 147–15,730 |
| Daily bars | 886 |
| Perf Week | +0.15% |
| Perf Month | +2.02% |
| Perf Quarter | −9.37% |
| Perf Half Y | −16.58% |
| Perf Year | +0.33% |
| Perf YTD | −11.83% |
| Prev Day | −2.00% |
| Clavix | B+ |
| Debt / Eq | 0.61 |
| Curr Ratio | 0.94 |
| Int Cover | 10.1× |
| FCF Margin | 13.0% |
| Rev Growth | +6.4% |
| Profit | Profitable |
| Leverage | Low |
| Sector rank | 8 / 15 |
Clavix risk grade
regraded every trading dayAZN grades B+, 76 of 100. Steadiest on Macro Resilience (64), most exposed on News Sentiment (56, mixed). 1 of the 4 weighted dimensions sit above the Pharmaceuticals median. Ranks 8 of 15 in Pharmaceuticals by Clavix score.
How rough the ride is
| AZN | Pharmaceuticals median | |
|---|---|---|
| Betavs the overall market · lower is steadier | 1.39 | 0.43 |
| Volatilityannualized | 34.7% | 10.7% |
| Max drawdown, past yearworst peak-to-trough fall | −25.7% | — |
| Typical daily movemedian absolute daily change | 0.97% | — |
| Days beyond ±3%of the last 252 sessions | 177% | — |
How its days are spread
Daily returns over the last 252 sessions in 1% bins. Moves beyond ±6% land in the end bins.
52-week range
The bar runs from the lowest to the highest close of the last 252 sessions; the marker is the latest close.
Drawdown from the 1-year peak
Percent below the running high over the last 12 months. Zero is a fresh high.
Market sensitivity
| AZN | Pharmaceuticals median | |
|---|---|---|
| Beta to the markethow much it swings with the S&P 500 · lower is safer | 1.39 | 0.43 |
| Macro sensitivityrate, dollar and credit exposure bucket | High | Low67% of 15 |
Where it sits on the macro scale
Low means rates, the dollar and credit spreads barely move it. Very High means they drive a large share of its swings. The counts are how many Pharmaceuticals names sit in each bucket.
Where it ranks in its sector
Rank by Clavix score within the sector. Right is the top of the sector.
Price performance
| AZN | |
|---|---|
| 1 week | +0.2% |
| 1 month | +2.0% |
| Year to date | −11.8% |
| 1 year | +0.3% |
Context for the rank, not itself a risk measure.
Recent coverage, scored
| AZN | |
|---|---|
| Articles scoredthe most recent scored coverage, up to 30 | 30since 29 Jul |
| Average score0 most bearish, 100 most bullish | 53 |
| Bullish · bearisharticles above 60 · below 40 | 15 · 12 |
| Directionarticles whose tone is improving vs worsening | 15 ↑ 12 ↓ |
Where the article scores land
Each bar is a 10-point band of article scores. Below 40 reads bearish, above 60 bullish.
Balance sheet, against the sector
The shaded band is the middle half of the 15 Pharmaceuticals names Clavix covers; the tick is the sector median.
Growth
| AZN | |
|---|---|
| Revenue growthyear over year | +6.4% |
Financial Health is shown but does not count toward the grade. Why
0–100, higher is safer. The tick on each bar is the Pharmaceuticals median. Click a dimension for the evidence behind it. Financial Health is shown but does not count toward the grade.
Against Pharmaceuticals
15 companies| Metric | AZN | Sector spread | Median |
|---|---|---|---|
| Beta | 1.39 | 0.43 | |
| Volatility | 34.7% | 10.7% | |
| Debt / equity | 0.61 | 0.94 | |
| Current ratio | 0.94 | 1.86 | |
| FCF margin | 13.0% | 20.8% | |
| Interest coverage | 10.1× | 5.9× |
Recent news
most recent scored articles · the chip is the article’s score · click to openAstraZeneca's stock is down 20% over the past six months, weighed down by setbacks in its drug development pipeline. The article argues that blockbuster drugs, growth in cancer treatments, and a strong lineup of upcoming launches are reasons to keep holding the stock.
AstraZeneca said its SANOVO trial met its main goal: combining Tagrisso with Orpathys as the first treatment for patients with non-small cell lung cancer that has a specific EGFR gene mutation lengthened the time before the disease got worse (progression-free survival).
AstraZeneca said a late-stage Chinese trial showed that combining its cancer drugs Tagrisso and Orpathys significantly extended the time before the disease worsened (called progression-free survival) when used as a first treatment for a type of lung cancer.
Shares of Ionis and AstraZeneca fell after full data from the late-stage CARDIO-TTRansform trial showed it missed its primary goal, a result the companies had first flagged on July 9. Jefferies said the readout carries a neutral-to-negative readthrough for Alnylam (ALNY).
AstraZeneca's experimental heart disease drug failed a late-stage (Phase 3) clinical trial. The drug, called a silencer, showed no extra benefit for patients with a progressive heart condition called ATTR-CM who were already taking a different type of drug called a stabilizer, and that lack of effect tanked the entire study.
Nearest peers by size
Pharmaceuticals| Ticker | Company | Grade | Mkt cap | P/E | Beta | |
|---|---|---|---|---|---|---|
| PFE | Pfizer Inc | A- | $164.2B | 37.74 | 0.27 | Compare |
| BMY | Bristol-Myers Squibb Co | B+ | $139.1B | 14.87 | 0.19 | Compare |
| MRK | Merck & Co Inc | B+ | $375.8B | 116.50 | 0.14 | Compare |
| JNJ | Johnson & Johnson | A- | $671.0B | 31.85 | 0.21 | Compare |
| RPRX | Royalty Pharma PLC | A | $36.73B | 45.07 | 0.38 | Compare |
| ZTS | Zoetis Inc | B | $31.87B | 12.03 | 0.69 | Compare |
| LLY | Eli Lilly and Co | B | $1.09T | 40.31 | 0.43 | Compare |
| VTRS | Viatris Inc | B+ | $20.71B | — | 0.91 | Compare |
You just read one holding. Clavix reads the whole portfolio.
Every position you own, graded on the same five dimensions, with an alert when a grade moves. Three months free on iPhone.